Immunodeficiency 33 (IMD33) Cell Models for Research

Immunodeficiency 33 (IMD33) is a rare primary immunodeficiency disorder caused by mutations in the STAT5B gene. It is inherited in an autosomal recessive manner. The exact prevalence is unknown, but it is extremely rare, with fewer than 50 cases reported worldwide. The condition is characterized by recurrent infections, chronic lung disease, growth hormone insensitivity, and autoimmune manifestations. The clinical severity varies, but without treatment, the prognosis is poor, with many patients succumbing to infections or respiratory failure in childhood or early adulthood. Early diagnosis and management, including immunoglobulin replacement and hematopoietic stem cell transplantation, can improve outcomes. The disease is listed in the WHO International Classification of Diseases (ICD-11) under primary immunodeficiencies.

IMD33 provides a valuable model for studying the JAK-STAT signaling pathway, particularly the role of STAT5B in immune cell development and function. The disease is a natural 'knockout' of STAT5B, offering insights into its pleiotropic effects. Research focuses on understanding the molecular mechanisms underlying the immune defects, growth hormone insensitivity, and autoimmune manifestations. Public datasets, such as those from the NCBI Gene Expression Omnibus (GEO), contain transcriptomic data from patient samples and cell lines, facilitating mechanistic studies. Open questions include the precise role of STAT5B in regulatory T cell function and the potential for targeted therapies.

While IMD33 is not a cancer, the underlying pathway (JAK-STAT) is frequently dysregulated in cancers. The major pathways affected include:

• • JAK-STAT signaling: STAT5B is a key transcription factor downstream of cytokine receptors. Mutations lead to loss of function, impairing immune cell proliferation and differentiation.
• • Growth hormone signaling: STAT5B mediates growth hormone receptor signaling, explaining growth failure.
• • Immune regulation: STAT5B is critical for regulatory T cell development and function, leading to autoimmunity.
• • Steps in the JAK-STAT pathway:

1. Cytokine binds to receptor.

2. JAK kinases phosphorylate receptor.

3. STAT5B is recruited and phosphorylated.

4. STAT5B dimerizes and translocates to nucleus.

5. STAT5B regulates gene expression.

Data from ClinVar and literature. Most mutations are homozygous or compound heterozygous.

STAT5B loss affects multiple signaling networks:

• • JAK-STAT network: Impaired signaling downstream of IL-2, IL-7, IL-15, and growth hormone receptors.
• • PI3K/AKT pathway: Cross-talk with STAT5B; altered immune cell survival.
• • MAPK pathway: Indirect effects on proliferation.
• • Key nodes affected:
• • Cytokine receptors (IL2RA, IL7R, IL15RA)
• • JAK1, JAK2, JAK3
• • STAT5B (mutated)
• • Target genes: BCL2, MYC, PIM1, SOCS2

Organoids: Intestinal organoids can be generated from patient-derived iPSCs to study immune-epithelial interactions, though not widely used for IMD33.

• • STAT5B knockout mice: Display growth retardation, impaired immune function, and autoimmunity, recapitulating IMD33.
• • STAT5B conditional knockout mice: Tissue-specific deletion to study cell-type-specific roles.
• • Patient-derived xenografts (PDX): Not applicable for IMD33 as it is not a cancer.
• • Induced models: CRISPR-generated STAT5B knockout in human cell lines.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with STAT5B knockout or knock-in mutations. These models are valuable for studying the functional consequences of specific mutations. For example:

• • STAT5B knockout Jurkat cells: Used to study T cell signaling and proliferation.
• • STAT5B knock-in cell lines with patient-specific mutations (e.g., p.A630P): Used to assess dominant-negative effects.

Commercially available, sequence-verified models accelerate research by providing consistent and validated tools. These models are generated using CRISPR technology and are available from various commercial sources.

Gene-edited cell lines are used to validate the role of STAT5B in immune cell function. For example, STAT5B knockout in Jurkat cells leads to decreased IL-2-induced proliferation and reduced expression of target genes like BCL2. Knock-in of patient mutations can confirm pathogenicity and help study genotype-phenotype correlations.

Isogenic pairs (wild-type vs. STAT5B knockout) can be used to screen for compounds that rescue or bypass STAT5B deficiency. This is relevant for developing therapies for IMD33 and for cancers with STAT5B dysregulation. Resistance mechanisms to JAK inhibitors can be studied using STAT5B-mutant cell lines.

CRISPR screens in STAT5B-deficient cells can identify synthetic lethal partners, which may serve as therapeutic targets. For example, targeting alternative JAK-STAT pathways or downstream effectors could be explored. Gene expression profiling of knockout cells can reveal biomarkers for disease monitoring.